Skip to search formSkip to main contentSkip to account menu

OSI 027

Known as: Mammalian Target of Rapamycin Kinase Inhibitor OSI-027, mTOR Kinase Inhibitor OSI-027, OSI-027 
An orally bioavailable mammalian target of rapamycin (mTOR) kinase inhibitor with potential antineoplastic activity. mTOR kinase inhibitor OSI-027… 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (2)

ImidazolesTriazines
NCIt Antineoplastic Agent Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Effect of ARK5 on the anti-tumour activity of OSI-027 via regulation of epithelial-mesenchymal transition in pancreatic cancer.
e15758 Background: Pancreatic cancer (PC) is one of the most common lethal malignancies,OSI-027, a selective inhibitor of mTOR… 
2017
2017
OSI‐027 modulates acute graft‐versus‐host disease after liver transplantation in a rat model
Despite its rarity (1%‐2%), acute graft‐versus‐host disease after liver transplantation (LT‐aGVHD) has a high mortality rate (85… 
2017
2017
MHY1485 ameliorates UV-induced skin cell damages via activating mTOR-Nrf2 signaling
Ultra Violet (UV)-caused skin cell damage is a main cause of skin cancer. Here, we studied the activity of MHY1485, a mTOR… 
2016
2016
Identification of mTOR as a primary resistance factor of the IAP antagonist AT406 in hepatocellular carcinoma cells
Dysregulation of inhibitor of apoptosis (IAP) proteins (IAPs) in hepatocellular carcinoma (HCC) is often associated with poor… 
2012
2012
Targeted immunosuppression: no longer naïve.
2011
2011
Preclinical Development Preclinical Characterization of OSI-027 , a Potent and Selective Inhibitor of mTORC 1 and mTORC 2 : Distinct from Rapamycin
The phosphoinositide 3-kinase (PI3K)/AKT/mTOR pathway is frequently activated in human cancers, and mTOR is a clinically… 
2010
2010
OSI-027, a Dual TORC1/TORC2 Inhibitor, Induces Bim- and Puma-Mediated Apoptosis In Lymphoid Malignancy
Abstract 970 The mammalian target of rapamycin, mTOR, is a highly conserved serine/threonine kinase known to play a role in… 
2010
2010
Targeted Inhibition of mTORC1 and mTORC2 by the Active-Site mTOR Inhibitors, PP-242 and OSI-027, Has Cytotoxic Effects In T-Cell Acute Lymphoblastic Leukemia
Abstract 3242 T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive form of leukemia characterized by uncontrolled… 
2010
2010
Dual Inhibition of mTORC1/mTORC2 Induces Apoptosis of Mantle Cell Lymphoma by Preventing Rictor Mediated AKTS473 Phosphorylation by Potentiating AKT2-PHLPP1 Association
Abstract 772 The mammalian target of rapamycin (mTOR) plays a crucial role in proliferative and anti-apoptotic signals in various… 
2010
2010
Abstract 4486: OSI-027, a selective dual mTORC1/TORC2 kinase inhibitor displays broad spectrum anti-tumor activity in preclinical models of human cancer
Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC The mammalian target of rapamycin (mTOR) protein… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)